Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 22.48 Thousand USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 18.03 Thousand USD | -71.34% |
| 2020 | 62.92 Thousand USD | 74.19% |
| 2019 | 36.12 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 795.45 Thousand USD | 5.95% |
| 2012 | 750.77 Thousand USD | 5.25% |
| 2011 | 713.33 Thousand USD | 67.31% |
| 2010 | 426.36 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 157.46 Thousand USD | 10.89% |
| 2006 | 142 Thousand USD | -4.53% |
| 2005 | 148.74 Thousand USD | -20.11% |
| 2004 | 186.19 Thousand USD | 15.65% |
| 2003 | 161 Thousand USD | 5.57% |
| 2002 | 152.51 Thousand USD | -5.5% |
| 2001 | 161.38 Thousand USD | -9.76% |
| 2000 | 178.83 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 12.37 Thousand USD | 0.0% |
| 2024 Q1 | 17.5 Thousand USD | -100.0% |
| 2023 Q1 | 36.52 Thousand USD | 0.0% |
| 2023 FY | 22.48 Thousand USD | 0.0% |
| 2023 Q2 | 31.93 Thousand USD | -12.56% |
| 2023 Q4 | 22.48 Thousand USD | -17.52% |
| 2023 Q3 | 27.25 Thousand USD | -14.65% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | - USD | -100.0% |
| 2022 FY | - USD | -100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2021 Q1 | 112.94 Thousand USD | 79.48% |
| 2021 Q3 | 49.88 Thousand USD | -39.18% |
| 2021 Q4 | 18.03 Thousand USD | -63.85% |
| 2021 FY | 18.03 Thousand USD | -71.34% |
| 2021 Q2 | 82.03 Thousand USD | -27.37% |
| 2020 Q1 | 31.77 Thousand USD | -12.06% |
| 2020 FY | 62.92 Thousand USD | 74.19% |
| 2020 Q4 | 62.92 Thousand USD | -35.11% |
| 2020 Q3 | 96.97 Thousand USD | -22.48% |
| 2020 Q2 | 125.09 Thousand USD | 293.76% |
| 2019 FY | 36.12 Thousand USD | 0.0% |
| 2019 Q1 | 50.04 Thousand USD | 0.0% |
| 2019 Q2 | 46.2 Thousand USD | -7.69% |
| 2019 Q3 | 42.29 Thousand USD | -8.46% |
| 2019 Q4 | 36.12 Thousand USD | -14.58% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | 767.06 Thousand USD | -1.81% |
| 2014 FY | - USD | -100.0% |
| 2014 Q3 | 749.11 Thousand USD | -2.34% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q1 | 781.23 Thousand USD | -1.79% |
| 2013 Q2 | 763.15 Thousand USD | 9.13% |
| 2013 Q3 | 809.44 Thousand USD | 6.06% |
| 2013 Q4 | 795.45 Thousand USD | -1.73% |
| 2013 FY | 795.45 Thousand USD | 5.95% |
| 2013 Q1 | 699.32 Thousand USD | -6.85% |
| 2012 Q4 | 750.77 Thousand USD | 2.4% |
| 2012 Q1 | 757.17 Thousand USD | 6.14% |
| 2012 Q2 | 745.4 Thousand USD | -1.55% |
| 2012 FY | 750.77 Thousand USD | 5.25% |
| 2012 Q3 | 733.17 Thousand USD | -1.64% |
| 2011 Q4 | 713.33 Thousand USD | -1.05% |
| 2011 Q3 | 720.88 Thousand USD | -1.06% |
| 2011 Q1 | 735.01 Thousand USD | 72.39% |
| 2011 Q2 | 728.63 Thousand USD | -0.87% |
| 2011 FY | 713.33 Thousand USD | 67.31% |
| 2010 FY | 426.36 Thousand USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | 426.36 Thousand USD | -0.24% |
| 2010 Q3 | 427.39 Thousand USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q1 | 25.85 Thousand USD | -83.58% |
| 2007 Q2 | 138.84 Thousand USD | -1.44% |
| 2007 Q1 | 140.87 Thousand USD | -0.8% |
| 2007 Q4 | 157.46 Thousand USD | 15.09% |
| 2007 FY | 157.46 Thousand USD | 10.89% |
| 2007 Q3 | 136.81 Thousand USD | -1.46% |
| 2006 Q4 | 142 Thousand USD | -1.16% |
| 2006 FY | 142 Thousand USD | -4.53% |
| 2006 Q3 | 143.67 Thousand USD | -1.13% |
| 2006 Q2 | 145.31 Thousand USD | -1.1% |
| 2006 Q1 | 146.93 Thousand USD | -1.22% |
| 2005 FY | 148.74 Thousand USD | -20.11% |
| 2005 Q4 | 148.74 Thousand USD | 1.21% |
| 2005 Q1 | 151.05 Thousand USD | -18.87% |
| 2005 Q2 | 149.01 Thousand USD | -1.35% |
| 2005 Q3 | 146.96 Thousand USD | -1.37% |
| 2004 Q1 | 158.15 Thousand USD | -1.77% |
| 2004 Q3 | 153.44 Thousand USD | -1.44% |
| 2004 Q2 | 155.69 Thousand USD | -1.56% |
| 2004 FY | 186.19 Thousand USD | 15.65% |
| 2004 Q4 | 186.19 Thousand USD | 21.35% |
| 2003 Q4 | 161 Thousand USD | -30.9% |
| 2003 FY | 161 Thousand USD | 5.57% |
| 2003 Q1 | 149.39 Thousand USD | -2.05% |
| 2003 Q2 | 158.8 Thousand USD | 6.3% |
| 2003 Q3 | 232.98 Thousand USD | 46.71% |
| 2002 Q4 | 152.51 Thousand USD | -1.35% |
| 2002 Q1 | 270.07 Thousand USD | 67.35% |
| 2002 FY | 152.51 Thousand USD | -5.5% |
| 2002 Q2 | 157.37 Thousand USD | -41.73% |
| 2002 Q3 | 154.6 Thousand USD | -1.76% |
| 2001 Q4 | 161.38 Thousand USD | 6.09% |
| 2001 Q3 | 152.13 Thousand USD | -1.24% |
| 2001 FY | 161.38 Thousand USD | -9.76% |
| 2001 Q1 | 172.13 Thousand USD | -3.74% |
| 2001 Q2 | 154.04 Thousand USD | -10.51% |
| 2000 Q4 | 178.83 Thousand USD | -0.26% |
| 2000 Q3 | 179.3 Thousand USD | 0.0% |
| 2000 FY | 178.83 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Journey Medical Corporation | 14.62 Million USD | 99.846% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.993% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.975% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.996% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 95.829% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 95.829% |
| SCYNEXIS, Inc. | 12.15 Million USD | 99.815% |
| Safety Shot Inc | 304.9 Thousand USD | 92.626% |
| Alpha Teknova, Inc. | 13.25 Million USD | 99.83% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.995% |
| Bright Green Corporation | 201.78 Thousand USD | 88.857% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.991% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.996% |
| Cosmos Health Inc. | 3.03 Million USD | 99.259% |
| PainReform Ltd. | 30 Thousand USD | 25.053% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | 80.804% |
| Embecta Corp. | 1.62 Billion USD | 99.999% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 99.831% |
| Procaps Group, S.A. | 28.41 Million USD | 99.921% |
| Theratechnologies Inc. | 51.26 Million USD | 99.956% |
| Harrow Health, Inc. | 183.17 Million USD | 99.988% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | 74.156% |
| Biofrontera Inc. | 804 Thousand USD | 97.203% |
| DURECT Corporation | 2.7 Million USD | 99.168% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 99.932% |
| Cronos Group Inc. | 1.55 Million USD | 98.558% |
| OptiNose, Inc. | 611 Thousand USD | 96.32% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.995% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 99.934% |
| RedHill Biopharma Ltd. | 455 Thousand USD | 95.058% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 99.963% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 99.824% |
| Radius Health, Inc. | 339.66 Million USD | 99.993% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 99.781% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.995% |
| Procaps Group S.A. | 28.41 Million USD | 99.921% |
| Alvotech | 1.02 Billion USD | 99.998% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 99.656% |
| Viatris Inc. | 16.18 Billion USD | 100.0% |
| Rockwell Medical, Inc. | 8.29 Million USD | 99.729% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 99.793% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | 93.308% |
| Tilray Brands, Inc. | 287.93 Million USD | 99.992% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 99.981% |
| Shineco, Inc. | 10.01 Million USD | 99.776% |
| PetIQ, Inc. | 437.82 Million USD | 99.995% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | 89.293% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.991% |
| Alimera Sciences, Inc. | 64.48 Million USD | 99.965% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 99.942% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | 83.356% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 99.672% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | 96.877% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 99.931% |
| Hempacco Co., Inc. | 5.93 Million USD | 99.621% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.998% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 99.96% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.996% |
| Currenc Group, Inc. | 2.5 Million USD | 99.103% |
| Kamada Ltd. | 7.43 Million USD | 99.698% |
| Indivior PLC | 235.66 Million USD | 99.99% |
| Evoke Pharma, Inc. | 5 Million USD | 99.55% |
| Flora Growth Corp. | 942 Thousand USD | 97.613% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | 0.0% |
| Evolus, Inc. | 120.35 Million USD | 99.981% |
| HUTCHMED (China) Limited | 48.18 Million USD | 99.953% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.996% |
| Akanda Corp. | 2.49 Million USD | 99.1% |